Limits...
Methylation pattern of CDH13 gene in digestive tract cancers.

Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A - Br. J. Cancer (2004)

Bottom Line: Recently, the loss of CDH13 (T-cadherin, H-cadherin) gene expression accompanied by CDH13 promoter methylation was identified in colon cancers.We examined CDH13 methylation in oesophageal and gastric carcinomas.These results suggested that CDH13 might play a variety of roles depending on the tissue type.

View Article: PubMed Central - PubMed

Affiliation: Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan. khibi@med.nagoya-u.ac.jp

ABSTRACT
Recently, the loss of CDH13 (T-cadherin, H-cadherin) gene expression accompanied by CDH13 promoter methylation was identified in colon cancers. We examined CDH13 methylation in oesophageal and gastric carcinomas. Five of 37 oesophageal cancers (14%) and 23 of 66 gastric cancers (35%) demonstrated abnormal methylation of the CDH13 promoter. Abnormal methylation was frequently found in gastric cancers of patients at all clinical stages just as in E-cadherin, another of the cadherin family, suggesting that these cancers could be methylated at an early stage. These results suggested that CDH13 might play a variety of roles depending on the tissue type.

Show MeSH

Related in: MedlinePlus

Representative MSP of CDH13 promoter in digestive tract cancer cell lines. The presence of a visible PCR product in lane U indicates the presence of unmethylated genes; the presence of PCR product in lane M indicates the presence of methylated genes. All colon cancer cell lines (SW1083, SW1222, and SW1417) and two gastric cancer cell lines (NUGC3 and NUGC4) that demonstrated only methylation of the CDH13 promoter lacked CDH13 gene expression, while CDH13 was expressed in other cell lines with unmethylation of the CDH13 promoter.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2747686&req=5

fig1: Representative MSP of CDH13 promoter in digestive tract cancer cell lines. The presence of a visible PCR product in lane U indicates the presence of unmethylated genes; the presence of PCR product in lane M indicates the presence of methylated genes. All colon cancer cell lines (SW1083, SW1222, and SW1417) and two gastric cancer cell lines (NUGC3 and NUGC4) that demonstrated only methylation of the CDH13 promoter lacked CDH13 gene expression, while CDH13 was expressed in other cell lines with unmethylation of the CDH13 promoter.

Mentions: We first examined the methylation status of CDH13 in digestive tract cancer cell lines using MSP. DNA from all three colorectal cancer cell lines (SW1083, SW1222, and SW1417), two of three gastric cancer cell lines (MKN1, NUGC3, and NUGC4), and none of three oesophageal cancer cell lines (TE1, NUEC1, and NUEC2) exhibited abnormal promoter methylation of CDH13 gene (Figure 1Figure 1


Methylation pattern of CDH13 gene in digestive tract cancers.

Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A - Br. J. Cancer (2004)

Representative MSP of CDH13 promoter in digestive tract cancer cell lines. The presence of a visible PCR product in lane U indicates the presence of unmethylated genes; the presence of PCR product in lane M indicates the presence of methylated genes. All colon cancer cell lines (SW1083, SW1222, and SW1417) and two gastric cancer cell lines (NUGC3 and NUGC4) that demonstrated only methylation of the CDH13 promoter lacked CDH13 gene expression, while CDH13 was expressed in other cell lines with unmethylation of the CDH13 promoter.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2747686&req=5

fig1: Representative MSP of CDH13 promoter in digestive tract cancer cell lines. The presence of a visible PCR product in lane U indicates the presence of unmethylated genes; the presence of PCR product in lane M indicates the presence of methylated genes. All colon cancer cell lines (SW1083, SW1222, and SW1417) and two gastric cancer cell lines (NUGC3 and NUGC4) that demonstrated only methylation of the CDH13 promoter lacked CDH13 gene expression, while CDH13 was expressed in other cell lines with unmethylation of the CDH13 promoter.
Mentions: We first examined the methylation status of CDH13 in digestive tract cancer cell lines using MSP. DNA from all three colorectal cancer cell lines (SW1083, SW1222, and SW1417), two of three gastric cancer cell lines (MKN1, NUGC3, and NUGC4), and none of three oesophageal cancer cell lines (TE1, NUEC1, and NUEC2) exhibited abnormal promoter methylation of CDH13 gene (Figure 1Figure 1

Bottom Line: Recently, the loss of CDH13 (T-cadherin, H-cadherin) gene expression accompanied by CDH13 promoter methylation was identified in colon cancers.We examined CDH13 methylation in oesophageal and gastric carcinomas.These results suggested that CDH13 might play a variety of roles depending on the tissue type.

View Article: PubMed Central - PubMed

Affiliation: Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan. khibi@med.nagoya-u.ac.jp

ABSTRACT
Recently, the loss of CDH13 (T-cadherin, H-cadherin) gene expression accompanied by CDH13 promoter methylation was identified in colon cancers. We examined CDH13 methylation in oesophageal and gastric carcinomas. Five of 37 oesophageal cancers (14%) and 23 of 66 gastric cancers (35%) demonstrated abnormal methylation of the CDH13 promoter. Abnormal methylation was frequently found in gastric cancers of patients at all clinical stages just as in E-cadherin, another of the cadherin family, suggesting that these cancers could be methylated at an early stage. These results suggested that CDH13 might play a variety of roles depending on the tissue type.

Show MeSH
Related in: MedlinePlus